Meet our doctors Last reviewed: 02 Jun 2026 Sources A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (STEP UP), Diabetes & endocrinology [accessed 26 September 2025] MHRA approves GLP1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, GOV.UK [accessed 26 September 2025] Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval, Reuters [accessed 26 September 2025] Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial, The Lancet [accessed 26 September 2025] Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen (PIL), emc [accessed 26 September 2025]
Disposal practices for unwanted residential medications in the United States
Comorbidities remission after Roux-en-Y gastric bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain
(About a third to a quarter of total weight lost is from lean body mass.) When you consume less food relative to what you expend, your body taps into its fat and muscle reserves for energy
Interestingly, GLP-1RA-based drugs have been proven beneficial to some extent in dedicated trials and should be considered in patients with obesity and/or T2D and metabolic dysfunction-associated steatohepatitis (MASH) 90
